The 25th Annual Mary Mulready Sullivan Oncology Symposium addresses many of the interesting and perplexing challenges surrounding breast cancer screening, diagnosis, treatment, and support. The recently announced alliance between the Hartford HealthCare Cancer Institute and the Memorial Sloan-Kettering Cancer Center will promote the development of state-of-the-art standards for cancer diagnosis and treatment for Connecticut residents, and make available cutting-edge research trials. We are particularly pleased to host internationally renowned Memorial Sloan-Kettering Cancer Center clinician scientists who will give their perspective on these most interesting topics.
Dr. Lisa Sclafani from MSK’s department of Surgery will discuss the evolution of surgical management. Dr. Maura Dickler, Breast Program Medical Oncologist from MSK, will present specific strategies concerning neoadjuvant therapy, Her2 positive tumors, and triple negative tumors. Dr. Beryl McCormick, from MSK’s department of Radiation Oncology, will discuss new radiation approaches. Mary McCabe, RN, MN, also from the Breast Program at MSK, will discuss Cancer Survivorship programs.
Dr. Larry Norton, internationally recognized expert in cancer and its therapy will discuss Translational Science and where we may all be heading in breast cancer therapeutics over the next decade. Three Hartford Hospital experts will present updates: Dr. Jennifer Logan, Director of Breast Imaging, will discuss Imaging Controversies, Dr. Andrew Ricci, Jr., Senior Pathologist, will discuss Papillary Breast Carcinoma, and Sara Carroll, Genetics Counselor, will discuss Breast Cancer Genetics Counseling issues. Following these informative presentations, lunch will be served and there will be an opportunity for the audience to ask questions of our panel and participate in an active discussion.
The 25th Annual Mary Mulready Sullivan Oncology Symposium, Advances in Breast Cancer: Treatment and Survivorship, is an excellent opportunity for physicians, nurses, and other healthcare providers to receive state-of-the-art information concerning breast cancer treatment and support.
View the conference brochure for a schedule and more information.
CMEs will be awarded.